OVR110 Antibody Compositions and Methods of Use

Abstract

The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.

1 . An isolated Ovr110 antibody that binds to Ovr110 on a mammalian cell in vivo. 
     
     
         2 . The antibody of  claim 1  which internalizes upon binding to Ovr110 on a mammalian cell in vivo. 
     
     
         3 . The antibody of  claim 1  which is a monoclonal antibody, an antibody fragment, a chimeric antibody or a humanized antibody. 
     
     
         4 - 5 . (canceled) 
     
     
         6 . The antibody of  claim 1  which is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5180, PTA-5855, PTA-5856 and PTA-5884 or which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5180, PTA-5855, PTA-5856 and PTA-5884. 
     
     
         7 . (canceled) 
     
     
         8 . The antibody of  claim 1  which is conjugated to a growth inhibitory agent or a cytotoxic agent. 
     
     
         9 - 13 . (canceled) 
     
     
         14 . The antibody of  claim 1 , wherein the mammalian cell is a cancer cell. 
     
     
         15 . (canceled) 
     
     
         16 . The Ovr110 antibody of  claim 1  that inhibits the growth of Ovr110-expressing cancer cells in vivo. 
     
     
         17 . The antibody of  claim 16  which is a humanized or human antibody. 
     
     
         18 . The antibody of  claim 17  which is produced in bacteria. 
     
     
         19 . (canceled) 
     
     
         20 . The antibody of  claim 16 , wherein the cancer cells are from a cancer selected from the group consisting of ovarian, pancreatic, lung and breast cancer. 
     
     
         21 . The antibody of  claim 20 , wherein the cancer is ovarian, pancreatic, lung or breast cancer. 
     
     
         22 - 24 . (canceled) 
     
     
         25 . A composition comprising the antibody of  claim 1 , and a carrier. 
     
     
         26 - 29 . (canceled) 
     
     
         30 . A method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with the antibody of  claim 1 , thereby killing the cancer cell. 
     
     
         31 - 48 . (canceled) 
     
     
         49 . An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of  claim 1 . 
     
     
         50 . The article of manufacture of  claim 49  further comprising a package insert indicating that the composition can be used to treat ovarian, pancreatic, lung or breast cancer. 
     
     
         51 - 60 . (canceled) 
     
     
         61 . A method for detecting Ovr110 overexpression in a subject in need thereof comprising,
 (a) combining a serum sample of a subject with an Ovr110 antibody of  claim 1  under conditions suitable for specific binding of the Ovr110 antibody to Ovr110 in said serum sample   (b) determining the level of Ovr110 in the serum sample, and   (c) comparing the level of Ovr110 determined in step b to the level of Ovr110 in a control,   wherein an increase in the level of Ovr110 in the serum sample from the subject as compared to the control is indicative of Ovr110 overexpression in the subject.   
     
     
         62 . The method of  claim 61  wherein the subject has cancer. 
     
     
         63 . The method of  claim 62  wherein the subject has breast or ovarian cancer. 
     
     
         64 . The method of  claim 63  wherein the ovarian cancer is an ovarian serous adenocarcinoma and the breast cancer is a breast infiltrating ductal carcinoma or metastatic cancer. 
     
     
         65 . The method of  claim 61  wherein the control is a serum sample from a subject without a cancer overexpressing Ovr110. 
     
     
         66 - 71 . (canceled) 
     
     
         72 . The antibody of  claim 1  which also binds to a rodent homolog of Ovr110. 
     
     
         73 . The antibody of  claim 1  which binds to Ovr110 with a binding affinity of 10 −9  to 10 −13  M. 
     
     
         74 . The antibody of  claim 1  which binds to deglycosylated Ovr110.